Chronic administration of adenosine A 3 receptor agonist and cerebral ischemia: neuronal and glial effects

By Von Lubitz D.K.J.E.   Lin R.C.-S.   Boyd M.   Norbert Bischofberger   Jacobson K.A.  

European Journal of Pharmacology, Vol. 367, Iss. 2, 1999-02 ,pp. : 157-163

Elsevier

Access to resources Recommend Favorite

Istradefylline, a novel adenosine A_2A receptor antagonist, for the treatment of Parkinson’s disease

By Jenner Peter  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 729-738

Informa Healthcare

Access to resources Recommend Favorite

Repeated treatment with adenosine A 1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene

By De Sarro G.   Donato Di Paola E.   Falconi U.   Ferreri G.   De Sarro A.  

European Journal of Pharmacology, Vol. 317, Iss. 2, 1996-12 ,pp. : 239-245

Elsevier

Access to resources Recommend Favorite

Lack of tolerance to motor stimulant effects of a selective adenosine A 2A receptor antagonist

By Halldner  

European Journal of Pharmacology, Vol. 406, Iss. 3, 2000-10 ,pp. : 345-354

Elsevier

Access to resources Recommend Favorite

Adenosine receptor ligands: differences with acute versus chronic treatment

By Jacobson K.A.   von Lubitz D.K.J.E.   Daly J.W.   Fredholm B.B.  

Trends in Pharmacological Sciences, Vol. 17, Iss. 3, 1996-03 ,pp. : 108-113

Elsevier

Access to resources Recommend Favorite